Beyond Sinus Rhythm: Rhythm Control and Mechanism-Based Secondary Prevention in Atrial Fibrillation–Related Stroke
Abstract
Atrial fibrillation is one of the most important causes of ischemic stroke and it is strongly associated with recurrent stroke, systemic embolism, heart failure, cognitive decline, and mortality. Oral anticoagulation, preferably direct oral anticoagulants, remains the cornerstone of secondary stroke prevention in patients with atrial fibrillation and a history of ischemic stroke. However, ischemic stroke may still occur despite appropriate anticoagulation therapy, a condition often referred to as breakthrough ischemic stroke. This residual risk reflects heterogeneous mechanisms, including inadequate anticoagulant exposure, atrial cardiomyopathy, left atrial appendage thrombus, large-artery atherosclerosis, small-vessel disease, cancer-associated thrombosis, and other competing etiologies. Rhythm control has re-emerged as a disease-modifying strategy after the EAST-AFNET 4 trial, and its prespecified subgroup analysis suggested a potential benefit in patients with prior stroke. However, the recently reported STABLED randomized clinical trial, which specifically evaluated catheter ablation in addition to edoxaban-based standard therapy after a recent ischemic stroke, did not demonstrate a significant reduction in recurrent ischemic stroke, systemic embolism, all-cause mortality, or hospitalization for heart failure. These findings do not negate the value of rhythm control for symptom relief, atrial fibrillation burden reduction, and selected cardiovascular outcomes; however, they challenge the assumption that the restoration of sinus rhythm alone is sufficient for secondary stroke prevention. Future strategies should integrate optimized anticoagulation and early rhythm control when appropriate, with a systematic evaluation of competing stroke mechanisms, vascular risk factor control, and selected left atrial appendage interventions. The next frontier is not rhythm control alone but rhythm control embedded within mechanism-based secondary stroke prevention.
Related
- Antithrombotic Therapy for Secondary Stroke Prevention in Patients With Symptomatic Large‐Artery Atherosclerosis and Atrial Fibrillation: A Multicenter Experience
- Low-threshold secondary and tertiary suicide prevention measures for individuals with suicid-related thoughts and behaviors: a scoping review
- Association between anticholinergic burden and geographic atrophy secondary to age-related macular degeneration: a case-control study.
- Low-dose colchicine for the prevention of postoperative atrial fibrillation after bypass surgery: Results from the COLPOAF study
- Atrial fibroblast metabolic reprogramming in atrial fibrillation: a candidate mechanism within multicellular atrial cardiomyopathy
BibTeX
@article{nishiyama2026beyond,
title = {{Beyond Sinus Rhythm: Rhythm Control and Mechanism-Based Secondary Prevention in Atrial Fibrillation–Related Stroke}},
author = {Yasuhiro Nishiyama},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2026},
month = oct,
doi = {10.5551/jat.rv22055},
url = {https://www.jstage.jst.go.jp/article/jat/33/10/33_RV22055/_article},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Beyond Sinus Rhythm: Rhythm Control and Mechanism-Based Secondary Prevention in Atrial Fibrillation–Related Stroke
AU - Yasuhiro Nishiyama
PY - 2026
DA - 2026/10/01
JO - Journal of Atherosclerosis and Thrombosis
DO - 10.5551/jat.rv22055
UR - https://www.jstage.jst.go.jp/article/jat/33/10/33_RV22055/_article
AB - Atrial fibrillation is one of the most important causes of ischemic stroke and it is strongly associated with recurrent stroke, systemic embolism, heart failure, cognitive decline, and mortality. Oral anticoagulation, preferably direct oral anticoagulants, remains the cornerstone of secondary stroke prevention in patients with atrial fibrillation and a history of ischemic stroke. However, ischemic stroke may still occur despite appropriate anticoagulation therapy, a condition often referred to as breakthrough ischemic stroke. This residual risk reflects heterogeneous mechanisms, including inadequate anticoagulant exposure, atrial cardiomyopathy, left atrial appendage thrombus, large-artery atherosclerosis, small-vessel disease, cancer-associated thrombosis, and other competing etiologies. Rhythm control has re-emerged as a disease-modifying strategy after the EAST-AFNET 4 trial, and its prespecified subgroup analysis suggested a potential benefit in patients with prior stroke. However, the recently reported STABLED randomized clinical trial, which specifically evaluated catheter ablation in addition to edoxaban-based standard therapy after a recent ischemic stroke, did not demonstrate a significant reduction in recurrent ischemic stroke, systemic embolism, all-cause mortality, or hospitalization for heart failure. These findings do not negate the value of rhythm control for symptom relief, atrial fibrillation burden reduction, and selected cardiovascular outcomes; however, they challenge the assumption that the restoration of sinus rhythm alone is sufficient for secondary stroke prevention. Future strategies should integrate optimized anticoagulation and early rhythm control when appropriate, with a systematic evaluation of competing stroke mechanisms, vascular risk factor control, and selected left atrial appendage interventions. The next frontier is not rhythm control alone but rhythm control embedded within mechanism-based secondary stroke prevention.
SN - 1880-3873
SN - 1340-3478
ER -